PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site

December 27, 2023 02:37 PM AEDT | By Cision

PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site — Image source: Kalkine Media

Recent News

The Scotts Miracle-Gro Foundation and KidsGardening Announce the 2025...

Westwater Resources Receives Letter of Interest from US EXIM Bank for...

Cantor downgrades Marvell Technology: Potential catalysts ’few and far...

Honeywell rises as BofA upgrades stock to Buy on a return to positive...

NANJING, China, Dec. 27, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API (HPAPI) GMP facility (OEB-5 and above) at its Zhejiang manufacturing site.

The new HPAPI GMP facility enables PharmaBlock to offer process R&D and kilo-scale production of HPAPIs and ADC toxins. It spans an area of 1000 m², and is equipped with multifunctional rigid isolators, reactors ranging from 20 L to 100 L. The facility allows handling of potent compounds with Occupational Exposure Limit (OEL) as low as 50 ng/m³(OEB-5 and above). In addition to this new GMP HPAPI facility, multiple workshops at PharmaBlock Zhejiang are capable to manufacture OEB-4 compounds.

Rigid isolators and reactors in the clean room

Currently, PharmaBlock is enhancing its capabilities to provide research, development, and manufacturing services for new modalities, including targeted protein degraders, peptides, oligonucleotides, and ADCs, offering partners with comprehensive and highly flexible solutions. In the ADC field, the company is enriching its library of linker-payload intermediates and building blocks to support ADC drug R&D. It can also provide ADC chemistry CMC services, including linker-payload synthesis and ADC conjugation. The company has successfully delivered process development and kilogram-scale production of several innovative linkers, and process optimization of payloads. The new HPAPI GMP facility is a crucial addition to support the delivery of ADC projects to global partners.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.